SenesTech (SNES) AI Stock Analysis

• Market Cap: $16.02M
• Dividend Yield: N/A
• Average Volume (3M): 121.59K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.23
• Revenue Growth: 36.89%
• EPS Growth: 91.74%
• Country: US
• Employees: 23
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Chemicals - Specialty
• EPS (TTM): -0.87
• Shares Outstanding: 5,185,333
• 10 Day Avg. Volume: 95,347
• 30 Day Avg. Volume: 121,592
• PEG Ratio: <0.01
• Price to Book (P/B): 0.92
• Price to Sales (P/S): 1.24
• P/FCF Ratio: -0.38
• Enterprise Value/Market Cap: 0.38
• Enterprise Value/Revenue: 2.90
• Enterprise Value/Gross Profit: 4.53
• Enterprise Value/Ebitda: -1.03
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: $4.00 ▲(17.99% Upside)

SenesTech's overall stock score is primarily influenced by its financial performance challenges, with ongoing profitability and cash flow issues. Technical indicators suggest bearish market momentum, and valuation metrics are weak. However, the positive sentiment from the earnings call, driven by record revenue and strategic growth, provides some optimism.

Positive Factors

Revenue Growth

The record revenue growth indicates strong market demand and successful product adoption, positioning SenesTech for continued expansion in its core markets.

Product Sales Expansion

The significant increase in Evolve product sales highlights the company's ability to innovate and capture market share, reinforcing its competitive position in pest management.

International Expansion

International agreements expand SenesTech's market reach, diversifying revenue streams and reducing reliance on domestic markets, which supports long-term growth.

Negative Factors

Profitability Challenges

Ongoing profitability issues, with negative EBIT and net income, could hinder SenesTech's ability to reinvest in growth and manage operational expenses effectively.

Cash Flow Struggles

Persistent negative cash flows indicate financial strain, potentially limiting SenesTech's ability to fund operations and strategic initiatives without external financing.

Decline in ContraPest Sales

The significant decline in ContraPest sales suggests challenges in maintaining product relevance and market share, which could impact overall revenue stability.

SenesTech Business Overview & Revenue Model

Company Description

SenesTech, Inc. develops a technology for managing animal pest populations through fertility control. It offers ContraPest, a liquid bait that limits reproduction of male and female rats. The company was incorporated in 2004 and is headquartered in Phoenix, Arizona.

How the Company Makes Money

SenesTech generates revenue primarily through the sale of its flagship product, ContraPest, to various markets including agriculture, food production, and urban pest control. The company employs a direct sales model alongside partnerships with pest control service providers and agricultural distributors to enhance product reach. Additional revenue streams may include licensing agreements for its technology and potential collaborations with governmental and environmental organizations focused on sustainable pest management solutions. The company's strategic partnerships with pest control professionals and agricultural entities further bolster its market presence and revenue potential.

SenesTech Financial Statement Overview

Summary

SenesTech shows potential with revenue growth and a stable balance sheet, but faces challenges in achieving profitability and positive cash flows. Ongoing net losses and negative cash flow hinder financial health, necessitating a focus on operational efficiency.

Income Statement

SenesTech has shown some revenue growth, with a significant increase from $1,193,000 in 2023 to $1,857,000 in 2024. However, the company is still struggling with profitability, as evidenced by the negative EBIT and net income. The gross profit margin has improved, but the net profit margin remains non-existent due to zero net income in 2024. These factors result in a moderate score, reflecting positive revenue trends but ongoing profitability challenges.

Balance Sheet

The balance sheet indicates a stable equity position with a decrease in total liabilities over the years. The debt-to-equity ratio is low, showing conservative leverage. However, the return on equity is weak due to persistent net losses, limiting the score to an average level. The company's financial stability is supported by a solid equity base, but profitability issues weigh heavily.

Cash Flow

SenesTech's cash flow statement reveals challenges with negative operating and free cash flows, despite some improvement in free cash flow from 2023 to 2024. The operating cash flow to net income ratio cannot be calculated for 2024 due to zero net income. The company has relied on financing activities to manage cash needs, reflecting ongoing cash flow struggles and reducing the score.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.09M	1.86M	1.19M	1.02M	576.00K	258.00K
Gross Profit	1.34M	1.00M	539.00K	464.00K	220.00K	-23.00K
EBITDA	-5.91M	-6.01M	-7.57M	-9.51M	-7.95M	-7.62M
Net Income	-4.43M	-6.18M	-7.71M	-9.71M	-8.27M	-7.94M
Balance Sheet
Total Assets	10.37M	3.28M	7.29M	6.78M	11.50M	6.02M
Cash, Cash Equivalents and Short-Term Investments	6.05M	1.31M	5.39M	4.78M	9.33M	3.64M
Total Debt	2.69M	262.00K	406.00K	359.00K	555.00K	1.44M
Total Liabilities	3.39M	767.00K	942.00K	1.50M	1.47M	2.14M
Stockholders Equity	6.98M	2.51M	6.35M	5.28M	10.04M	3.88M
Cash Flow
Free Cash Flow	-5.45M	-6.12M	-7.71M	-8.75M	-7.88M	-7.22M
Operating Cash Flow	-5.32M	-6.03M	-7.57M	-8.58M	-7.78M	-7.11M
Investing Cash Flow	-126.00K	-56.00K	-149.00K	-170.00K	-99.00K	-67.00K
Financing Cash Flow	9.53M	2.00M	8.34M	4.20M	13.56M	8.88M

SenesTech Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.39
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SNES, the sentiment is Negative. The current price of 3.39 is below the 20-day moving average (MA) of 3.59, below the 50-day MA of 4.20, and below the 200-day MA of 3.55, indicating a bearish trend. The MACD of -0.28 indicates Positive momentum. The RSI at 42.69 is Neutral, neither overbought nor oversold. The STOCH value of 26.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SNES.

SenesTech Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NTIC	67 Neutral	$77.88M	27.35	4.18%	1.23%	3.46%	-34.80%
FSI	62 Neutral	$105.68M	35.58	8.06%	―	-1.52%	6.38%
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
SNES	48 Neutral	$16.02M	-0.57	-119.89%	―	36.89%	91.74%
GURE	48 Neutral	$6.21M	-0.17	-17.63%	―	-15.26%	73.10%
LOOP	48 Neutral	$75.91M	-6.45	―	―	11013.00%	39.85%

SenesTech Corporate Events

SenesTech Appoints Michael Edell as Interim COO

On October 15, 2025, SenesTech appointed Michael Edell as Interim Chief Operating Officer. Mr. Edell, who has a background in founding and directing companies in the eco-friendly consumer goods and pet treat industries, will receive a monthly compensation of $30,000 and be eligible for bonuses, but will not receive standard benefits or severance due to the interim nature of the position.

The most recent analyst rating on (SNES) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on SenesTech stock, see the SNES Stock Forecast page.

SenesTech Registers Additional Shares for Market Offering

On September 24, 2025, SenesTech filed a prospectus supplement to register an additional $7,580,675 of shares of its common stock, as part of an At The Market Offering Agreement with H.C. Wainwright & Co., LLC, initially dated June 20, 2024. Prior to this filing, the company had already sold $3,048,894.72 worth of shares under this agreement, indicating an ongoing strategy to raise capital through stock offerings.

The most recent analyst rating on (SNES) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on SenesTech stock, see the SNES Stock Forecast page.

SenesTech Shines in Earnings Call with Record Revenue

In a recent earnings call, SenesTech showcased a robust performance, marked by record revenue and profit margins. The positive sentiment was driven by the success of their Evolve product line and significant expansion across e-commerce and municipal sales channels. Despite some challenges in agricultural applications and brick-and-mortar retail expansion, the overall outlook remains optimistic, with positive highlights significantly outweighing the lowlights.

SenesTech Reports Record Revenue and Growth in Q2 2025

SenesTech, Inc., headquartered in Surprise, Arizona, is a pioneering company in the field of fertility control for managing animal pest populations, specifically known for its EPA-registered rodent birth control products. The company has positioned itself as a leader in providing sustainable and humane pest management solutions.

SenesTech Enters New Warrant Agreements for Funding

On August 4, 2025, SenesTech entered into agreements with certain warrant holders to exercise existing warrants for 1,458,872 shares of common stock at $4.15 per share, generating gross proceeds of approximately $6.3 million. In return, the company will issue new short-term warrants for 2,188,308 shares at $5.25 per share, with the proceeds intended for working capital and general corporate purposes. The transactions, facilitated by H.C. Wainwright & Co., LLC, are expected to close around August 5, 2025, and include issuing placement agent warrants. The new warrants are unregistered and have a fifteen-month expiration post-registration statement effectiveness.

The most recent analyst rating on (SNES) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on SenesTech stock, see the SNES Stock Forecast page.